New developments in the incretin concept
- PMID: 3902545
- DOI: 10.1007/BF00281990
New developments in the incretin concept
Abstract
Experimental and clinical work over the last 6 years has confirmed and broadened, but also challenged, the incretin concept. The nervous component of the entero-insular axis is still poorly defined, especially the peptidergic nerves, of which several contain insulinotropic regulatory peptides. The incretin effect is preserved after complete denervation of the porcine pancreas. Type 2 (non insulin-dependent) diabetic patients have a significantly decreased incretin effect. GIP (gastric inhibitory polypeptide; glucose dependent insulin releasing peptide) remains the strongest incretin factor. Its secretion depends on the absorption of nutrients. However, the correlation between the GIP response and disturbances of the entero-insular axis in some gastrointestinal diseases and, in particular, Type 2 diabetes, is poor. Furthermore, physiological concentrations of exogenous GIP do not produce fully the incretin effect and injection of GIP antibodies does not abolish the incretin effect. This suggests the existence of additional humoral incretin factors. On the other hand, GIP seems to have direct metabolic effects independent of its insulinotropic activity. The incretin effect of oral glucose is smaller if plasma levels of C-peptide rather than insulin are measured. However, decreased hepatic extraction of insulin after glucose ingestion only accounts partially for the incretin effect. GIP is unlikely to be the gut factor which regulates hepatic insulin extraction.
Similar articles
-
Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.Diabetes. 2004 Dec;53 Suppl 3:S190-6. doi: 10.2337/diabetes.53.suppl_3.s190. Diabetes. 2004. PMID: 15561910 Review.
-
[Physiology and pathology of the entero-insular axis].Schweiz Med Wochenschr. 1985 Jul 20;115(29):970-3. Schweiz Med Wochenschr. 1985. PMID: 3901250 German.
-
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.J Clin Endocrinol Metab. 1993 Apr;76(4):912-7. doi: 10.1210/jcem.76.4.8473405. J Clin Endocrinol Metab. 1993. PMID: 8473405 Clinical Trial.
-
Entero-insular axis and diabetes mellitus.Horm Metab Res Suppl. 1992;26:13-8. Horm Metab Res Suppl. 1992. PMID: 1490680 Review.
-
Overview of incretin hormones.Horm Metab Res. 2004 Nov-Dec;36(11-12):742-6. doi: 10.1055/s-2004-826157. Horm Metab Res. 2004. PMID: 15655702 Review.
Cited by
-
Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.Pharmacol Rev. 2016 Oct;68(4):954-1013. doi: 10.1124/pr.115.011395. Pharmacol Rev. 2016. PMID: 27630114 Free PMC article. Review.
-
Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy.Dig Dis Sci. 1991 Oct;36(10):1361-70. doi: 10.1007/BF01296800. Dig Dis Sci. 1991. PMID: 1914756
-
GLP-1: target for a new class of antidiabetic agents?J R Soc Med. 2004 Jun;97(6):270-4. doi: 10.1177/014107680409700604. J R Soc Med. 2004. PMID: 15173327 Free PMC article. No abstract available.
-
Gut Metabolite Trimethylamine N-Oxide Protects INS-1 β-Cell and Rat Islet Function under Diabetic Glucolipotoxic Conditions.Biomolecules. 2021 Dec 17;11(12):1892. doi: 10.3390/biom11121892. Biomolecules. 2021. PMID: 34944536 Free PMC article.
-
Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists.Cardiovasc Diabetol. 2014 Oct 22;13:142. doi: 10.1186/s12933-014-0142-7. Cardiovasc Diabetol. 2014. PMID: 25338737 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical